Grupo de Investigación Clínica en Oncología Radioterapia
12
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
2 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)
Role: lead
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
Role: lead
OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment
Role: lead
Clinical Study Assessing the Effect of ZIVEREL® in Cancer Patients
Role: lead
Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
Role: lead
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19
Role: lead
Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma
Role: lead
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer
Role: lead
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Role: lead
FMISO-PET in Brain Tumors and SCS Effect
Role: collaborator
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
Role: lead
Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
Role: lead
All 12 trials loaded